These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Prabmechai N, Vannaprasaht S, Chumworathayi P, Chen P, Sritipsukho P. Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164 [Abstract] [Full Text] [Related]
4. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Wu XT, Hu FY, An DM, Yan B, Jiang X, Kwan P, Stefan H, Zhou D. Epilepsy Behav; 2010 Nov; 19(3):405-8. PubMed ID: 20833111 [Abstract] [Full Text] [Related]
8. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschini N, Barocci F, Ribizzi G, Cutrupi V, Cairoli R, Rapisarda V, Pastorello EA, Barocci S. Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408 [Abstract] [Full Text] [Related]
9. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M, RegiSCAR study group. Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896 [Abstract] [Full Text] [Related]
12. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Mahasirimongkol S, Teerawattananon Y. Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569 [Abstract] [Full Text] [Related]
18. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K, Kulkantrakorn K, Choonhakarn C, Phonhiamhan S, Piyatrakul N, Aungaree T, Pongpakdee S, Yodnopaglaw P. Epilepsia; 2010 May; 51(5):926-30. PubMed ID: 20345939 [Abstract] [Full Text] [Related]